Search

Your search keyword '"Lenz HJ"' showing total 732 results

Search Constraints

Start Over You searched for: Author "Lenz HJ" Remove constraint Author: "Lenz HJ"
732 results on '"Lenz HJ"'

Search Results

1. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer

2. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors

3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)

4. BMAL1, ein Transkriptionsfaktor des zirkadianen Rhythmus, assoziiert mit Resistenz gegen Anti-VEGFA Therapie unter Bevacizumab im kolorektalen Karzinom

6. Prädiktive und prognostische Faktoren in der neoadjuvanten/adjuvanten Therapie gastrointestinaler Tumoren: Wunschdenken oder Realität?

7. Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009

8. Association of common gene variants in the WNT/beta-catenin pathway with colon cancer recurrence

9. SNP Array 6.0 Ergebnisse bei Respondern und Nonrespondern eines fortgeschrittenen Magenkarzinoms unter 5-FU und Cisplatin/ Irinotecan basierender Radiochemotherapie

11. Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence

12. Time course of regorafenib-associated adverse events in the phase III CORRECT study

13. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

14. Randomisierte, doppelblinde, placebo-kontrollierte Phase III Multicenterstudie (CORRECT) von Regorafenib plus Best Supportive Care (BSC) versus Placebo plus BSC bei Patienten (Pat) mit metastasiertem kolorektalem Karzinom (mCRC), die nach einer Standardtherapie progredient waren

15. Deconstructing statistical questions: discussion

17. Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).

22. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).

30. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment.

34. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

35. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials

36. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer

37. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

38. Health-related Quality of Life in the Phase III LUME-Colon 1 Study: Comparison and Interpretation of Results From EORTC QLQ-C30 Analyses

39. Consensus molecular subtyping of metastatic colorectal cancer expands biomarker-directed therapeutic benefit for patients with CMS1 and CMS2 tumors.

40. Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).

41. Plant-Based Diet and Survival Among Patients with Metastatic Colorectal Cancer.

42. Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer.

43. Exploring Predictive and Prognostic Biomarkers in Colorectal Cancer: A Comprehensive Review.

45. Understanding patient-derived tumor organoid growth through an integrated imaging and mathematical modeling framework.

47. Genomic, immunologic, and prognostic associations of TROP2 (TACSTD2) expression in solid tumors.

48. Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast to liver metastases in breast cancer.

49. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial.

50. HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405.

Catalog

Books, media, physical & digital resources